Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI.
Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI.
复制标题
在EOB-MRI的肝动物阶段，不可切除的肝细胞癌的特征和Lenvatinib的治疗反应具有同等强度。
DOI：
10.3390/cancers13143633
复制
发表时间：
2021-07-20
期刊：
影响因子：
5.2
通讯作者：
Sakamoto N
中科院分区：
文献类型：
--
作者：
Kubo A;Suda G;Kimura M;Maehara O;Tokuchi Y;Kitagataya T;Ohara M;Yamada R;Shigesawa T;Suzuki K;Kawagishi N;Nakai M;Sho T;Natsuizaka M;Morikawa K;Ogawa K;Ohnishi S;Sakamoto N
CTNNB 1（编码β-连环蛋白）改变的HCC对免疫检查点抑制剂具有耐药性，并且与可切除HCC中EOB-MRI肝胆期等高强度HCC相关。然而，EOB-MRI肝胆期等高信号不可切除HCC的患病率、特征、突变谱和治疗反应尚不清楚。在这项研究中，我们发现，患病率为13%，并且在EOB-MRI肝胆期伴和不伴等高强度的HCC之间，对乐伐替尼的反应没有差异。我们使用无细胞DNA分析了CTNNB-1突变，为它们与EOB-MRI肝胆期等高强度的相关性提供了支持。在肝细胞癌（HCC）中，CTNNB-1突变导致对免疫检查点抑制剂的耐药性，与可切除HCC中钆塞酸增强磁共振成像（EOB-MRI）肝胆期等高强度HCC相关;然而，缺乏对不可切除HCC的分析。本研究分析了EOB-MRI肝胆期等高强度不可切除HCC的患病率、特征、乐伐替尼应答和CTNNB-1突变频率。在52例接受乐伐替尼治疗的不可切除HCC患者中，EOB-MRI肝胆期等高强度的发生率为13%。所有患者均有多个HCC，3例患者在EOB-MRI肝胆期有多个等高信号HCC。在EOB-MRI肝胆期有或无等高强度的患者之间，乐伐替尼对无进展生存期和总生存期的应答相似。7例患者（分别有3例和4例患者患有不可切除的HCC，在EOB-MRI的肝胆期有或无等高强度）进行了遗传分析。在这些患者中，2例（67%，2/3）在EOB-MRI肝胆期具有等高强度的HCC患者携带CTNNB-1突变，而所有4例在EOB-MRI肝胆期没有等高强度的HCC患者均不携带CTNNB-1突变。本研究的发现对EOB-MRI肝胆期等高信号HCC的检测和治疗具有临床意义。
HCC with alterations in CTNNB1 (which encodes β-catenin) is resistant to immune checkpoint inhibitors and is associated with HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI in resectable HCC. However, the prevalence, characteristics, mutation profile, and treatment response in unresectable HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI are not well clarified. In this study, we showed that the prevalence was 13%, and the response to lenvatinib does not differ between HCC with and without iso-high intensity in the hepatobiliary phase of EOB-MRI. We analyzed CTNNB-1 mutations using cell-free DNA, providing support for their association with iso-high intensity in the hepatobiliary phase of EOB-MRI. In hepatocellular carcinoma (HCC), CTNNB-1 mutations, which cause resistance to immune checkpoint inhibitors, are associated with HCC with iso-high intensity in the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) in resectable HCC; however, analyses on unresectable HCC are lacking. This study analyzed the prevalence, characteristics, response to lenvatinib, and CTNNB-1 mutation frequency in unresectable HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI. In 52 patients with unresectable HCC treated with lenvatinib, the prevalence of iso-high intensity in the hepatobiliary phase of EOB-MRI was 13%. All patients had multiple HCCs, and 3 patients had multiple HCCs with iso-high intensity in the hepatobiliary phase of EOB-MRI. Lenvatinib response to progression-free survival and overall survival were similar between patients with or without iso-high intensity in the hepatobiliary phase of EOB-MRI. Seven patients (three and four patients who had unresectable HCC with or without iso-high intensity in the hepatobiliary phase of EOB-MRI, respectively) underwent genetic analyses. Among these, two (67%, 2/3) who had HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI carried a CTNNB-1 mutation, while all four patients who had HCC without iso-high intensity in the hepatobiliary phase of EOB-MRI did not carry the CTNNB-1 mutation. This study’s findings have clinical implications for the detection and treatment of HCC with iso-high intensity in the hepatobiliary phase of EOB-MRI.
登录
查看更多内容
影响因子：
11.2
作者：
Hoshida Y;Nijman SM;Kobayashi M;Chan JA;Brunet JP;Chiang DY;Villanueva A;Newell P;Ikeda K;Hashimoto M;Watanabe G;Gabriel S;Friedman SL;Kumada H;Llovet JM;Golub TR
通讯作者：
Golub TR
影响因子：
19.7
作者：
Kitao, Azusa;Zen, Yoh;Nakanuma, Yasuni
通讯作者：
Nakanuma, Yasuni
影响因子：
168.9
作者：
Roth, David;Nelson, David R.;Greaves, Wayne
通讯作者：
Greaves, Wayne
影响因子：
158.5
作者：
Finn, Richard S.;Qin, Shukui;Cheng, Ann-Lii
通讯作者：
Cheng, Ann-Lii
影响因子：
5.1
作者：
Jiao J;Watt GP;Stevenson HL;Calderone TL;Fisher-Hoch SP;Ye Y;Wu X;Vierling JM;Beretta L
通讯作者：
Beretta L